Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

inotuzumab ozogamicin

(ih-noh-TOO-zoo-mab OH-zoh-ga-MIH-sin)
A drug used to treat adults and children aged 1 year and older with B-cell acute lymphoblastic leukemia that is CD22 positive (expresses the protein CD22). It is used in patients whose cancer came back or did not get better with other treatment. It is also being studied in the treatment of other types of cancer. Inotuzumab ozogamicin contains a monoclonal antibody that binds to CD22, which is found on some leukemia cells. It also contains an anticancer drug, which may help kill cancer cells. Inotuzumab ozogamicin is a type of antibody-drug conjugate. Also called Besponsa.
Search NCI's Dictionary of Cancer Terms